Valneva (NASDAQ:VALN) Stock Price Up 6.1%

Valneva SE (NASDAQ:VALN - Get Free Report) shares were up 6.1% on Thursday . The stock traded as high as $8.22 and last traded at $8.22. Approximately 1,859 shares were traded during trading, a decline of 80% from the average daily volume of 9,146 shares. The stock had previously closed at $7.75.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on VALN shares. HC Wainwright reiterated a "buy" rating and set a $26.00 target price on shares of Valneva in a research note on Thursday, March 21st. Guggenheim dropped their price objective on shares of Valneva from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Friday, March 22nd.

Valneva Stock Performance

The stock has a market cap of $564.70 million, a price-to-earnings ratio of -5.15 and a beta of 2.25. The stock's 50-day moving average is $7.68 and its 200-day moving average is $9.64. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.65 and a quick ratio of 1.37.

Valneva (NASDAQ:VALN - Get Free Report) last posted its earnings results on Wednesday, March 20th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of $0.20 by ($0.70). The business had revenue of $45.12 million for the quarter, compared to analyst estimates of $45.06 million. Valneva had a negative net margin of 65.99% and a negative return on equity of 59.48%. Analysts anticipate that Valneva SE will post 0.11 EPS for the current fiscal year.

Institutional Investors Weigh In On Valneva

Several hedge funds and other institutional investors have recently modified their holdings of the stock. UBS Group AG bought a new stake in shares of Valneva during the 2nd quarter valued at about $31,000. Jane Street Group LLC lifted its stake in shares of Valneva by 85.9% in the 1st quarter. Jane Street Group LLC now owns 16,584 shares of the company's stock worth $569,000 after acquiring an additional 7,664 shares during the period. Finally, Bank of America Corp DE acquired a new stake in shares of Valneva in the 1st quarter worth approximately $858,000. Institutional investors own 11.39% of the company's stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.